Navigation Links
Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy
Date:7/11/2014

MISSISSAUGA, ON, July 11, 2014 /CNW/ - Sunovion Pharmaceuticals Canada Inc. (Sunovion) today announced that Health Canada approved APTIOMTM (eslicarbazepine acetate) for use as a once-daily adjunctive therapy for the treatment of partial-onset seizures in patients with epilepsy who are not satisfactorily controlled with conventional therapy.  APTIOMTM is not indicated for use in patients under 18 years of age.

Epilepsy is one of the most common neurological disorders and according to Epilepsy Canada, it affects 0.6% of the population and each year approximately 15,500 people learn they have epilepsy.  Partial-onset seizures are the most prevalent seizure type, accounting for 60% of new epilepsy diagnoses1 and approximately one third of patients do not have adequate seizure control5.

The approval of APTIOMTM is based on three Phase 3 randomized, double-blind, placebo-controlled, safety and efficacy trials (Studies BIA-2093-301, BIA-2093-302 and BIA-2093-304), which included more than 1,400 people living with partial-onset seizures inadequately controlled by one to three concomitant AEDs (including carbamazepine, lamotrigine, valproic acid and levetiracetam). In these global studies,  treatment with APTIOMTM demonstrated statistically significant reductions in standardized seizure frequency versus placebo, and significantly more APTIOMTM treated patients experienced seizure frequency reduction of 50% or more from baseline (41% compared to 22% for placebo-treated patients).

The most frequently reported adverse reactions in patients taking APTIOMTM were dizziness, somnolence, headache, nausea, diplopia, vomiting, fatigue, ataxia, vision blurred, and vertigo.

"The approval of APTIOMTM is an important milestone not only for our company, but for thousands of Canadians living with, and affected by epile
'/>"/>

SOURCE Sunovion Pharmaceuticals Canada Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders
2. Collaborations, FDA Approvals, Appointments, Patents, and Stock Movements - Research Report on Aetna, United Therapeutics, Perrigo, Arena Pharmaceuticals, and Keryx Biopharmaceuticals
3. Shimadzu’s New Aggregates Sizer Aggregation Analysis System for Biopharmaceuticals Enables Real-time Quantitative Analysis
4. Savient Receives Approval From Bankruptcy Court To Sell Substantially All Assets To Crealta Pharmaceuticals
5. Biotech Briefing: Advancing Biotechs Forging Ahead With Breaking News Developments: Alliqua, OncoMed Pharmaceuticals, EnteroMedics, Unilife, Amarin
6. Vanda Pharmaceuticals to Present at the 25th Annual Piper Jaffray Healthcare Conference
7. Actinium Pharmaceuticals Announces 2013 Annual Shareholder Meeting
8. Avanir Pharmaceuticals to Participate in Two Conferences in December
9. Jazz Pharmaceuticals Announces Participation at the Piper Jaffray Healthcare Conference on December 3
10. RXi Pharmaceuticals Reports Financial Results for the Third Quarter of 2013
11. RXi Pharmaceuticals Announces the Start of Their First Phase 2 Study with RXI-109 for Treatment of Hypertrophic Scars in Conjunction with Scar Revision Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... circuits are based on electrons, but one of the ... circuits, i.e. circuits based on light (photons) instead of ... create a stream of single photons and control their ... of attempts to achieve this control, but now scientists ... a steady stream of photons emitted one at a ...
(Date:8/29/2014)... 29, 2014 /PRNewswire/ - iCo Therapeutics ("iCo" or ... financial results for the six months ended June ... in Canadian dollars and presented under International Financial ... Highlights , Announced top-line results related ... endpoint for subjects enrolled in the Phase 2 ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 A major ... the biotech start-up dense realm of Boston-Cambridge, is gaining ... able investors. James Sherley, the Director of Boston’s Adult ... the local and national visibility of his company an ... 2013. , In addition to a social media marketing ...
(Date:8/28/2014)... 2014 Best Sanitizers, Inc., the first ... hand sanitizer, asks food processors and food handling professionals ... sanitizer they’re currently using to Best Sanitizers’ Alpet® ... critical to fighting cross-contamination and the spread of pathogens ... there are key criteria that make a hand sanitizer ...
Breaking Biology Technology:Breakthrough in light sources for new quantum technology 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 4The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 2The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 3The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 4Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 2Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 3
... and the University of California, Los Angeles (UCLA) have concluded ... chemistry for the rapid and robust labeling of proteins, peptides ... Emission Tomography (PET). "We are pleased ... cutting-edge work being developed by the Crump Institute," said Dr. ...
... Geim, a recipient of the 2010 Nobel Prize for graphene, ... electrons can magnetise graphene. The results, reported in ... the field of spintronics. Spintronics is a group of ... in addition to its fundamental electric charge that is exploited ...
... April 15, 2011 Carmell Therapeutics, a company that ... of injured tissues, has closed on a Series A ... facility and collect data for early clinical validation for ... was led by Harbor Light Capital Partners, a private ...
Cached Biology Technology:ImaginAb, Inc. Concludes Licensing Agreement With UCLA for Novel Radiochemistry Technology 2New spin on graphene 2Carmell Therapeutics Completes Series A Financing to Advance the Development of Novel Bioactive Plastics 2Carmell Therapeutics Completes Series A Financing to Advance the Development of Novel Bioactive Plastics 3
(Date:8/31/2014)... A fast-sensitive "electronic-nose" for sniffing the highly infectious bacteria ... stomach cramps, has been developed by a team at ... the research team has demonstrated that it is possible ... which would lead to rapid diagnosis of the ... could be possible to identify different strains of the ...
(Date:8/31/2014)... past several decades, malaria diagnosis has changed very little. After ... the blood across a glass slide, stains it with a ... parasite, which causes the disease. This approach gives an accurate ... an important measure of disease severity but is not ... research team from the Singapore-MIT Alliance for Research and Technology ...
(Date:8/29/2014)... from the University of Texas Medical Branch at Galveston has ... antibodies can completely protect monkeys against a lethal dose of ... time when the disease is severe. , Thomas Geisbert, professor ... Nature discussing advances in Ebola treatment research. The filoviruses ... most deadly of pathogens, with fatality rates of up to ...
Breaking Biology News(10 mins):Scientists develop 'electronic nose' for rapid detection of C. diff infection 2A new way to diagnose malaria 2A new way to diagnose malaria 3Leading Ebola researcher at UTMB says there's an effective treatment for Ebola 2
... , April 30, 2013 /PRNewswire-iReach/ -- Clinilabs, an early phase ... industry, today announced the arrival of Dr. Admir ... provide expertise in the development of drugs to treat pain, ... clinical trials. Dr. Admir Hadzic ...
... integrates three large sets of genomic data available through ... that might predict survival in patients with the most ... researchers at the Ohio State University Comprehensive Cancer Center ... Solove Research Institute (OSUCCC James) initially analyzed messenger ...
... whales sing complex songs in tropical waters during the ... latitudes at other times of the year. NOAA ... whale movements to acoustic behavior on a feeding ground ... published April 10 in the journal PLOS ONE ...
Cached Biology News:Clinilabs Welcomes Anesthesiologist Dr. Admir Hadzic Who Will Provide CSF/cCSF Capabilities For Clinilabs 2Big data analysis identifies prognostic RNA markers in a common form of breast cancer 2Researchers track singing humpback whales on a Northwest Atlantic feeding ground 2
... is used to perform runs with ... the Experion automated electrophoresis system. The ... simulated gel views and summarizes size, ... Results table. This software is for ...
... Top cover cold rolled steel with stove ... surface polyethylene Front, ... 3 UV lamps Internal ... interlocked with fluorescent light Lighting ...
...
... this set of Antibody Microarray slides ... a total of over 2100 spots,including ... control. Antibodies belonging to many important ... cycle progression, signal transduction and gene ...
Biology Products: